The CDC estimates that during the 2018-19 Influenza (flu) season, there were approximately 37.4 to 42.9 million flu illnesses, contributing to 17.3 to 20.1 million flu-related medical visits and between 531,000 to 647,000 flu-related hospitalizations. Many infections present with similar signs and symptoms, making it difficult to distinguish flu from other viral or bacterial respiratory illnesses.
- Adenovirus
- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus 229E
- Coronavirus OC43
- Human Metapneumovirus
- Human Rhinovirus/Enterovirus
- Influenza A
- Influenza A/H1
- Influenza A/H3
- Influenza A/H1-2009
- Influenza B
- Parainfluenza Virus 1
- Parainfluenza Virus 2
- Parainfluenza Virus 3
- Parainfluenza Virus 4
- Respiratory Syncytial Virus
- Bordetella parapertussis
- Bordetella pertussis
- Chlamydia pneumoniae
- Mycoplasma pneumoniae
Test Benefits
The Comprehensive Respiratory Panel may significantly reduce the duration of antibiotic use, the length of inpatient stay and the time patients spend in isolation. Improved clinical outcomes can result in cost savings, as well as increased patient satisfaction. With 97.1% Sensitivity and 99.3% Specificity, healthcare providers can rely on BioReference for accurate and dependable results.
When ordering tests, providers should only order tests that are medically necessary for the diagnosis or treatment of a patient, generally not for screening. Only a few screening tests are covered by most government and third party payers for certain conditions at specific intervals.
